Comparative risk of acute kidney injury among cancer patients treated with immune checkpoint inhibitors  

作　　者：Fei Liu ZixianWang Xiaofan Li Zhen Zhang Yue Yang Junquan Chen Dinghua Chen Lingling Wu Xiangyu Liu Sujun Han Fangming Wang Wasilijiang Wahafu Yibo Gao Shancheng Ren Nianzeng Xing Guangyan Cai Xiangmei Chen 

机构地区：[1]Department of Urology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,P.R.China [2]Laboratory of Translational Medicine,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,P.R.China [3]Department of Thoracic Surgery,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,P.R.China [4]Department of Medical Oncology,Sun Yat-sen University Cancer Center,Guangzhou,Guangdong,P.R.China [5]Department of Nephrology,First Medical Center of Chinese PLA General Hospital,Nephrology Institute of the Chinese People’s Liberation Army,State Key Laboratory of Kidney Diseases,National Clinical Research Center for Kidney Diseases,Beijing Key Laboratory of Kidney Disease Research,Beijing,P.R.China [6]Department of Plastic Surgery,Plastic Surgery Hospital,Chinese Academy of Medical Sciences,Peking Union Medical College,Beijing,PR China [7]State Key Laboratory of Molecular Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,P.R.China [8]Central Laboratory,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital&Shenzhen Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Shenzhen,Guangdong,P.R.China [9]Department of Urology,Shanghai Changzheng Hospital,Shanghai,P.R.China

出　　处：《Cancer Communications》2023年第2期214-224,共11页癌症通讯（英文）

基　　金：National Key R&D Program of China,Grant/Award Number:2020AAA0109500;National Natural Science Foundation of China,Grant/Award Numbers:82030025,32100631,82003269,82122053;Young Elite Scientists Sponsorship Program by the China Association for Science and Technology,Grant/Award Number:YESS20210056;CAMS Innovation Fund for Medical Sciences,Grant/Award Number:2021-I2M-1-067;Central Research Institute Fund of Chinese Academy of Medical Sciences,Grant/Award Number:2021-PT310-001;Key-Area Research and Development Program of Guangdong Province,Grant/Award Number:2021B0101420005。

摘　　要：With the development and introduction of immune checkpoint inhibitors(ICIs)in cancer patients,immune-related side effects have increasingly attracted attention.However,the risks of immune-related renal toxicity are poorly characterized.In this study,we performed a network meta-analysis(NMA)of ICI-related randomized clinical trials(RCTs)to elucidate the comparative risk of acute kidney injury(AKI)in cancer patients receiving different ICIs.We also sought to identify other factors potentially affecting the risk of AKI.PubMed and EMBASE were searched for peer-reviewed trial reports published between January 2000 and May 2021.Eligible studies were RCTs studying ICIs in cancer patients and reporting AKI data.We performed a frequentist NMA to evaluate the risk ratios for grade 1-5 and grade 3-5 AKI between the treatment groups.We also assessed the absolute incidence of AKI in the ICI-containing arm using traditional direct meta-analysis.Once significant heterogeneity was detected in a traditional direct meta-analysis,multivariable meta-regression analysis was applied to identify factors that significantly affected the absolute incidence of AKI.A total of 85 RCTs were included in this study.In the NMA for the risk of grade 1-5 and 3-5 AKI,ipilimumab showed a significantly higher risk than avelumab and durvalumab,whereas 1 mg/kg nivolumab plus 3 mg/kg ipilimumab(N1I3)showed a significantly higher risk than other groups.In terms of treatment ranking,durvalumab±low-dose tremelimumab and avelumab were consistently among the top three safest treatments for grade 1-5 or 3-5 AKI,whereas N1I3,ipilimumab and tremelimumab were consistently among the top three treatments with the highest risk for grade 1-5 or 3-5 AKI.Compared with other cancers,renal cell carcinoma and urothelial carcinoma showed a significantly higher risk of AKI.The incidence of AKI was significantly higher with ICI+chemotherapy than with ICI monotherapy.In this NMA involving largescale up-to-date ICI trials,we demonstrated the comparative safety of existing IC

关 键 词：immune checkpoint inhibitors acute kidney injury cancer immune therapy side effects 

分 类 号：R692[医药卫生—泌尿科学]